Sarah Parkinson, an analyst at RAND Europe, works across health innovation, public health and health services research. She is experienced in conducting literature reviews, interviews, surveys and both quantitative and qualitative analysis, as well as project management.
Her recent work includes studies looking at the use and impact of point of care testing for infectious diseases and electronic health records across EU/EEA Member States for the European Centre for Disease Control (ECDC), research into combating antimicrobial resistance through innovation, and the potential impact on the British insurance industry of predictive genetic testing and direct-to-consumer tests.
Parkinson has also worked on two studies around the Tobacco Products Directive and advertisements and promotions for tobacco and related products for the European Commission (DG SANTE), which looked specifically at the implications of e-cigarettes, heated tobacco products and other novel tobacco products, and new and emerging media channels for advertisements and promotions. She also contributes to healthcare services and quality improvement research, including through collaborative projects with academic institutions.
Prior to joining RAND Europe, Parkinson worked on projects related to prescription opioids and prescription drug monitoring programmes in the U.S. She holds an M.Sc. in social policy and a B.A. in cultural anthropology from the University of Pennsylvania.
Rodriguez-Rincon, D., Leach, B., Pollard, J., Parkinson, S., Gkousis, E., Lichten, C., Sussex, J., Manville, C., Exploring the societal burden of multiple sclerosis., RAND (RR-4262), 2019
Parks, S., Rodriguez-Rincon, D., Parkinson, S., Manville, C., The changing research landscape and reflections on national research assessment in the future, RAND (RR-3200), 2019
Parkinson, S., "Strengthening Prescription Drug Monitoring Program Mandates in the US," Public Sphere Journal of Public Policy (London School of Economics), 2018